Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:activeDuring |
acetaminophen
|
| gptkbp:administrativeDivision |
every 4 to 6 hours
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
generic
|
| gptkbp:clinicalTrials |
Phase 3
fever reduction acute pain management recommended for moderate to severe pain recommended for postoperative pain |
| gptkbp:contraindication |
allergic reaction
swelling itching skin rash severe liver disease |
| gptkbp:dosageForm |
solution
|
| gptkbp:drugInterdiction |
true
antipyretic analgesic rapid absorption half-life of 2 to 3 hours peak plasma concentration in 30 minutes |
| gptkbp:formulation |
injection
|
| gptkbp:hasPopulation |
children
adults |
| https://www.w3.org/2000/01/rdf-schema#label |
Ofirmev
|
| gptkbp:interactsWith |
alcohol
warfarin other hepatotoxic drugs |
| gptkbp:lastProduced |
2010
|
| gptkbp:mandates |
postoperative pain
|
| gptkbp:manufacturer |
Cadence Pharmaceuticals
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:United_States Europe |
| gptkbp:maxRange |
3000 mg per day
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:packaging |
vials
|
| gptkbp:route |
intravenous
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
headache
nausea vomiting hypotension |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
inhibits prostaglandin synthesis
|
| gptkbp:type |
acetaminophen injection
|
| gptkbp:usedFor |
pain relief
|
| gptkbp:waterManagement |
urine
|